Showing results (141-150 of 222) with videos related to

Sort By:
Pageof 23
The Journal of Infection|April 13, 2000
Successful treatment of Castleman's disease with HAART in two HIV-infected patientsM Lanzafame, G Carretta, M Trevenzoli, et al.
Infection|November 4, 2011
The effect of inappropriate therapy on bacteremia by ESBL-producing bacteriaF G De Rosa, N Pagani, L Fossati, et al.
European Review for Medical and Pharmacological Sciences|November 8, 2018
Optimising management of patients with hepatitis C virus in the age of direct-acting antivirals: results of a Delphi consensusV Di Marco, A Alberti, G Angarano, et al.
Nutrition, Metabolism, and Cardiovascular Diseases : NMCD|June 9, 2022
Sex-specific fat mass ratio cutoff value identifies a high prevalence of cardio-metabolic disorders in people living with HIVM Barale, M Massano, F Bioletto, et al.
HIV Clinical Trials|March 11, 2011
Maraviroc can improve lipid profiles in dyslipidemic patients with HIV: results from the MERIT trialA MacInnes, A Lazzarin, G Di Perri, et al.
Journal of Neuroimmune Pharmacology : the Official Journal of the Society on Neuroimmune Pharmacology|November 10, 2016
Blood Brain Barrier Impairment in HIV-Positive Naïve and Effectively Treated Patients: Immune Activation Versus AstrocytosisA Calcagno, A Romito, C Atzori, et al.
Journal of Endocrinological Investigation|August 1, 1984
High serum calcitonin levels in heroin addictsF Tagliaro, F Capra, R Dorizzi, et al.
International Journal of Antimicrobial Agents|January 29, 2020
Serum Trimethylamine-N-oxide Concentrations in People Living with HIV and the Effect of Probiotic SupplementationC Montrucchio, A De Nicolò, G D'Ettorre, et al.
The Journal of Antimicrobial Chemotherapy|March 24, 2017
Therapeutic drug monitoring of boosted PIs in HIV-positive patients: undetectable plasma concentrations and risk of virological failureA Calcagno, N Pagani, A Ariaudo, et al.
Pageof 23